Type 2 Diabetes Drug Could Benefit Patients With Type 1 Diabetes
Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, was associated with significant declines in blood sugar levels in patients with type 1 diabetes, according to the results of a recent study.
While dapagliflozin is approved for the treatment of type 2 diabetes, its effects on blood glucose levels in patients with poorly controlled type 1 diabetes are unknown.
________________________________________________________________________________
Exenatide-Dapagliflozin Combination Effective in Type 2 Diabetes
________________________________________________________________________________
The researchers conducted a double-blind, randomized, parallel-controlled, 3-arm, phase 3 study involving 833 patients aged 18 to 75 years who had inadequately controlled type 1 diabetes and who had been prescribed insulin for at least 12 months prior to the study. Due to a randomization error, 778 participants were included in the final analysis.
Following an 8-week lead-in period, the participants were randomly assigned to dapagliflozin 5 mg or 10 mg once daily, given orally, or to placebo. Primary outcomes included change from baseline HbA1c after 24 weeks of treatment.
After 24 weeks, both dapagliflozin groups saw significantly reduced HbA1c compared with the placebo group. The most common adverse events were nasopharyngitis, urinary tract infection, upper respiratory tract infection, and headache. Hypoglycemia occurred in 220, 235, and 207 patients in the dapagliflozin 5 mg, 10 mg, and placebo groups, respectively. Diabetic ketoacidosis occurred in 4, 5, and 3 patients in the dapagliflozin 5 mg, 10 mg, and placebo groups, respectively.
“Our results suggest that dapagliflozin is a promising adjunct treatment to insulin to improve glycemic control in patients with inadequately controlled type 1 diabetes,” the researchers concluded.
—Michael Potts
Reference:
Dandona P, Mathieu C, Phillip M, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial [published online September 14, 2017]. Lancet Diab Endo. doi: http://dx.doi.org/10.1016/S2213-8587(17)30308-X.